Insider Cluster (2 insiders) ·Filed Jun 16, 2026

USNA

USANA HEALTH SCIENCES INC
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $135K total
Actionable Insight • Neutral

These sales are small and likely reflect routine portfolio diversification or tax planning. No immediate catalyst is indicated. Monitor upcoming quarterly results for any fundamental deterioration, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
USNA ▼ -21.99% at T+60d
NEUTRAL call ✗ call lost -21.99% · α vs SPY -22.99% · entry $19.01 → $14.83
Entry anchored
Jun 16, 03:40 PM ET
via exchange tick
T+1d
-3.21%
call -3.21% · α -1.96%
$18.40
settled 4mo ago
T+5d
+1.00%
call +1.00% · α +3.23%
$19.20
settled 3mo ago
T+20d
+12.57%
call +12.57% · α +12.37%
$21.40
settled 3mo ago
T+60d
-21.99%
call -21.99% · α -22.99%
$14.83
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Two C-suite insiders at USANA Health Sciences (USNA) sold a combined $135K in open-market sales over a one-week window. The total is trivial relative to the $358M market cap (0.038%), and insider sales are weak directional signals. No material bearish read-through.

Key Financial Metrics

Direction
selling
Total Value
$135.0K
Insiders
2

Key Facts

  • Chief People Officer Paul A. Jones sold 5,600 shares at $18.50 for $103K on 2026-06-08
  • Chief Commercial Officer Brent Neidig sold 1,602 shares at $20.15 for $32K on 2026-06-12
  • Total cluster value of $135K represents 0.038% of USNA's $358M market cap
  • Recent 30-day insider activity includes 7 sells totaling $447K, consistent with routine diversification

Financial Impact

Total insider sales of $135K are immaterial relative to market cap

insider ownership

Risk Factors

  • Insider sales could accelerate if management sees headwinds, but current volume is negligible
  • USNA faces secular decline in direct-selling model; these sales may be precautionary

Market Snapshot

Exchange
NYSE
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-USNA-1781638960126
5 reports for USNA
Performance horizon
Filters
Rows
Reports for USNA — sortable, filterable
TypeNow
Jun 16, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$19.01 $21.40▲ +12.57%▲ +12.37%$14.82 (−22.04%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$19.01 $22.38▲ +17.73%▲ +16.28%$14.82 (−22.04%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.05 $21.72▲ +20.33%▲ +21.90%$14.82 (−17.89%)
May 29, 2026
18w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.30 $21.01▲ +14.81%▲ +16.60%$14.82 (−19.02%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$18.84 $20.70▲ +9.87%▲ +13.02%$14.82 (−21.34%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (34h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 16, 2026